Skip to Main content Skip to Navigation
Journal articles

Targeting actin inhibits repair of doxorubicin-induced DNA damage a novel therapeutic approach for combination therapy

Abstract : Severe side effects often restrict clinical application of the widely used chemotherapeutic drug doxorubicin. In order to decrease required substance concentrations, new concepts for successful combination therapy are needed. Since doxorubicin causes DNA damage, combination with compounds that modulate DNA repair could be a promising strategy. Very recently, a role of nuclear actin for DNA damage repair has been proposed, making actin a potential target for cancer therapy in combination with DNA-damaging therapeutics. This is of special interest, since actin-binding compounds have not yet found their way into clinics. We find that low-dose combination treatment of doxorubicin with the actin polymerizer chondramide B (ChB) synergistically inhibits tumor growth in vivo. On the cellular level we demonstrate that actin binders inhibit distinctive double strand break (DSB) repair pathways. Actin manipulation impairs the recruitment of replication factor A (RPA) to the site of damage, a process crucial for homologous recombination. In addition, actin binders reduce autophosphorylation of DNA-dependent protein kinase (DNA-PK) during nonhomologous end joining. Our findings substantiate a direct involvement of actin in nuclear DSB repair pathways, and propose actin as a therapeutic target for combination therapy with DNA-damaging agents such as doxorubicin.
Complete list of metadata

Cited literature [46 references]  Display  Hide  Download
Contributor : Laurent Jonchère Connect in order to contact the contributor
Submitted on : Wednesday, September 4, 2019 - 10:42:59 AM
Last modification on : Tuesday, May 24, 2022 - 3:16:04 PM
Long-term archiving on: : Thursday, February 6, 2020 - 1:41:01 AM


Publisher files allowed on an open archive




Lisa Pfitzer, Christina Moser, Florian Gegenfurtner, Anja Arner, Florian Foerster, et al.. Targeting actin inhibits repair of doxorubicin-induced DNA damage a novel therapeutic approach for combination therapy. Cell Death and Disease, Nature Publishing Group, 2019, 10 (4), pp.302. ⟨10.1038/s41419-019-1546-9⟩. ⟨hal-02119228⟩



Record views


Files downloads